LAG3 and arthritic joint disease: In comparison to PD-1/PD-L1 inhibitors, LAG-3 inhibition may increase the risk of arthritis due to enhanced T-cell dysregulation, whereas oral conditions may arise from extensive mucosal inflammation, highlighting the necessity for combination-specific irAE profiling; LAG-3 serves a complex function in immune modulation, exhibiting context-dependent effects that are especially pertinent in autoimmune conditions, where in mouse models of autoimmune diabetes.